Document is current
Any future updates will be listed below
-
Authors
Begum, Shahina https://orcid.org/0000-0002-3521-8865
Cabrera, Eliazar Sabater https://orcid.org/0000-0002-3184-2855
Restrepo, Oscar Herrera https://orcid.org/0000-0001-8193-999X
Burman, Cindy https://orcid.org/0009-0000-2860-1500
Sohn, Woo-Yun
Kuylen, Elise https://orcid.org/0000-0002-3528-5507
Shah, Hiral https://orcid.org/0000-0003-0204-451X
Kocaata, Zeki https://orcid.org/0000-0002-5231-3389
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 28 June 2024
First Online: 24 July 2024
Declarations
:
: Shahina Begum, Eliazar Sabater Cabrera, Oscar Herrera Restrepo, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Hiral Shah, and Zeki Kocaata are employed by and hold financial equities in GSK. The authors declare no other financial and non-financial relationships and activities.
: Institutional review board approval was received on 11/27/2022 from WCG IRB (IRB Tracking number 20226172). All survey respondents provided informed consent to participate in the study.
